

CITATION REPORT

List of articles citing

Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study

DOI: 10.1111/j.1439-0272.2006.00712.x
Andrologia, 2006, 38, 61-8.

Source: <https://exaly.com/paper-pdf/40348345/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
52	An overview of the diagnosis and treatment of erectile dysfunction. <i>Drugs</i> , 2006 , 66, 2339-55	12.1	17
51	The role of testosterone in erectile function and dysfunction. <i>The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender</i> , 2006 , 3, 292-298		1
50	Long-acting testosterone undecanoate for parenteral testosterone therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 709-721		4
49	Bibliography. Current world literature. Reconstructive surgery. <i>Current Opinion in Urology</i> , 2006 , 16, 460-38		
48	Significance of hypogonadism in erectile dysfunction. <i>World Journal of Urology</i> , 2006 , 24, 657-67	4	47
47	A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. <i>Aging Male</i> , 2007 , 10, 155-8	2.1	29
46	Effects of testosterone on erectile function: implications for the therapy of erectile dysfunction. <i>BJU International</i> , 2007 , 99, 988-92	5.6	36
45	Combination therapy with phosphodiesterase type V inhibitors and testosterone. <i>Current Sexual Health Reports</i> , 2008 , 5, 135-140	1.2	10
44	Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health. <i>Journal of Andrology</i> , 2008 , 29, 3-14		39
43	Testosterone and erectile dysfunction. <i>Journal of Andrology</i> , 2008 , 29, 593-604		48
42	The use of phosphodiesterase 5 inhibitors with concomitant medications. <i>Journal of Endocrinological Investigation</i> , 2008 , 31, 799-808	5.2	49
41	Erectile dysfunction and testosterone deficiency. <i>Frontiers of Hormone Research</i> , 2009 , 37, 108-122	3.5	44
40	Epidemiology and pathophysiology of male sexual dysfunction. <i>International Journal of Impotence Research</i> , 2008 , 20 Suppl 1, S3-10	2.3	24
39	Transdermal testosterone gel treatment of hypogonadal men. <i>Aging Health</i> , 2008 , 4, 517-528		1
38	Timetable of effects of testosterone administration to hypogonadal men on variables of sex and mood. <i>Aging Male</i> , 2009 , 12, 113-8	2.1	29
37	Testosterone and phosphodiesterase type-5 inhibitors: new strategy for preventing endothelial damage in internal and sexual medicine?. <i>Therapeutic Advances in Urology</i> , 2009 , 1, 179-97	3.2	15
36	Therapeutic potential of testosterone gels. <i>Aging Health</i> , 2009 , 5, 227-245		

35	Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. <i>Annals of Internal Medicine</i> , 2009 , 151, 639-49	8	58
34	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2009 , 151, 650-61	8	137
33	The role of testosterone in erectile dysfunction. <i>Nature Reviews Urology</i> , 2010 , 7, 46-56	5.5	115
32	Contemporary Treatment of Erectile Dysfunction. 2011 ,		2
31	Cardiovascular diseases and erectile dysfunction: the two faces of the coin of androgen deficiency. <i>Andrologia</i> , 2011 , 43, 1-8	2.4	19
30	Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). <i>Journal of Sexual Medicine</i> , 2011 , 8, 284-93	1.1	111
29	Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. <i>Journal of Sexual Medicine</i> , 2011 , 8, 3418-32	1.1	71
28	Testosterone replacement therapy in males with erectile dysfunction. <i>Journal of Pharmacy Practice</i> , 2011 , 24, 298-306	1.3	9
27	Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. <i>Aging Male</i> , 2012 , 15, 22-7	2.1	27
26	Testosterone and erection. 251-267		
25	Testosterone and Sexual Function. 2013 , 41-57		
24	Clinical Urologic Endocrinology. 2013 ,		
23	Treatment Strategy for Non-Responders to PDE5 Inhibitors. <i>World Journal of Men's Health</i> , 2013 , 31, 31-5	6.8	24
22	Synergetic effect of testosterone and phosphodiesterase-5 inhibitors. <i>Canadian Urological Association Journal</i> , 2013 , 6, 269	1.2	
21	Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone. <i>Journal of Sexual Medicine</i> , 2014 , 11, 543-52	1.1	12
20	Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. <i>Urology</i> , 2014 , 83, 1326-33	1.6	14
19	Male hypogonadism and metabolic syndrome. <i>Andrologia</i> , 2015 , 47, 579-86	2.4	14
18	Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. <i>World Journal of Men's Health</i> , 2016 , 34, 89-100	6.8	43

17	Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials. <i>Journal of Sexual Medicine</i> , 2016 , 13, 843-51	1.1	7
16	Effects of tadalafil treatment combined with physical activity in patients with low onset hypogonadism: results from a not-randomized single arm phase 2 study. <i>Aging Male</i> , 2016 , 19, 155-160	2.1	13
15	Effects of taking tadalafil 5mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. <i>Andrologia</i> , 2017 , 49, e12751	2.4	9
14	The Effect of Testosterone Replacement Therapy on Penile Hemodynamics in Hypogonadal Men With Erectile Dysfunction, Having Veno-Occlusive Dysfunction. <i>American Journal of Men's Health</i> , 2018 , 12, 634-638	2.2	10
13	Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. <i>Frontiers in Endocrinology</i> , 2019 , 10, 225	5.7	8
12	What are the benefits and harms of testosterone therapy for male sexual dysfunction?-a systematic review. <i>International Journal of Impotence Research</i> , 2019 , 31, 380-391	2.3	3
11	Effect of low androgen levels on the sulphur dioxide signalling pathway in rat penile corpus cavernosum. <i>Andrologia</i> , 2019 , 51, e13167	2.4	4
10	Practical Approaches to Treat ED in PDE5i Nonresponders. 2020 , 11, 1202-1218		3
9	Serum testosterone status in men with penile corporovenous-occlusive dysfunction. <i>Aging Male</i> , 2020 , 23, 1227-1231	2.1	
8	Combination therapy for erectile dysfunction: an update review. <i>Asian Journal of Andrology</i> , 2011 , 13, 382-90	2.8	24
7	Synergetic effect of testosterone and phosphodiesterase-5 inhibitors in hypogonadal men with erectile dysfunction: A systematic review. <i>Canadian Urological Association Journal</i> , 2012 , 6, 269-74	1.2	13
6	Testosterone replacement therapy: should it be performed in erectile dysfunction?. <i>Nephro-Urology Monthly</i> , 2013 , 5, 858-61	0.4	5
5	Introduction. 2007 , 1-9		
4	Hormonal Evaluation and Therapy in Erectile Dysfunction. 2011 , 161-177		
3	Testosterone and Anabolic Steroid Abuse. 2017 , 45-62		
2	Long-acting testosterone undecanoate for parenteral testosterone therapy. <i>Therapy: Open Access in Clinical Medicine</i> , 2006 , 3, 709-721		
1	The Impact of Testosterone on Erectile Function. 2022 , 3, 113-124		0